Premium
Treatment and Prophylaxis of Cytomegalovirus Disease: Authors' Reply
Author(s) -
Levinson Miriam L.,
Jacobson Pamala A.
Publication year - 1993
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1993.tb02708.x
Subject(s) - pharmacy , library science , medicine , center (category theory) , family medicine , computer science , chemistry , crystallography
From the Department of Pharmacy Services, University Medical Center, Tucson, Arizona (Dr. Levinson); and the Department of Pharmacy Services, University of Michigan Medical Center, Ann Arbor, Michigan (Dr. Jacobson). Address reprint requests to Pamala A. Jacobson, Pharm.D., Department of Pharmacy Services, University of Michigan Medical Center, UMH B2D 301, Box 0008, 1500 East Medical Center Drive, Ann Arbor, MI 48019-0008. presented, we find that the incidence of CMV pneumonia in seropositive patients who received IVlG was 10.9%, compared to an incidence of 14.9% in control patients. Although the difference in the incidence of CMV pneumonia was not significant, we still feel that the results of the study are encouraging. Results from further trials are necessary before a statement that IVlG definitely reduces CMV pneumonia can be made.